Soleno Therapeutics, Inc.

Soleno Therapeutics, Inc. is a clinical-stage biopharmaceutical company whose drug development pipeline requires animal testing as a core component of its preclinical research. The company's lead candidate, Diazoxide Choline Controlled-Release (DCCR) tablets for the treatment of Prader-Willi syndrome, has been studied extensively in animal models. Company disclosures and scientific publications reference the use of "numerous animal models of hyperphagic obesity" to demonstrate the drug's mechanism and efficacy prior to human trials.

Cruelty Free Investors lists Soleno Therapeutics for exploiting animals because the company conducts animal testing for its medical research and development. As a pharmaceutical company advancing novel therapeutics, Soleno's operations inherently involve commissioning and funding animal studies to meet regulatory requirements for investigational new drug applications, a standard industry practice that places it within the animal testing exclusion category.